Prognostic Score Including Gene Mutations in Chronic Myelomonocytic LeukemiaRaphaël Itzykson, Éric Solary, Daniel Birnbaum et al.|Journal of Clinical Oncology|2013Cited by 543
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasRaphaël Itzykson, Olivier Kosmider, Thomas Cluzeau et al.|Leukemia|2011Cited by 464
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myelomaFrédéric Pène, Didier Bouscary, Yann-Érick Claessens et al.|Oncogene|2002Cited by 298
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)Olivier Kosmider, Véronique Gelsi‐Boyer, Meyling Cheok et al.|Blood|2009Cited by 270
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathwaysJérôme Tamburini, Didier Bouscary, Nicolas Chapuis et al.|Blood|2007Cited by 252